PIV5-SARS CoV-2 vaccine
- Generic Name
- PIV5-SARS CoV-2 vaccine
A Phase 2 Trial of the Immunogenicity and Safety of CVXGA Intranasal COVID Vaccine in Healthy Adults
- First Posted Date
- 2023-02-21
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- CyanVac LLC
- Target Recruit Count
- 227
- Registration Number
- NCT05736835
- Locations
- 🇺🇸
Velocity Clinical Research, Cedar Park, Texas, United States
🇺🇸University of Rochester, Rochester, New York, United States
🇺🇸Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath